# A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma

> **NCT06102525** · PHASE1,PHASE2 · RECRUITING · sponsor: **Rznomics, Inc.** · enrollment: 43 (estimated)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** RZ-001
- **COMBINATION_PRODUCT:** VGCV

## Key facts

- **NCT ID:** NCT06102525
- **Lead sponsor:** Rznomics, Inc.
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-10-08
- **Primary completion:** 2029-03
- **Final completion:** 2029-05
- **Target enrollment:** 43 (ESTIMATED)
- **Last updated:** 2025-09-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06102525

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06102525, "A Study to Evaluate the Safety, Tolerability and Efficacy of RZ-001 With Valganciclovir (VGCV) in Subjects With Glioblastoma". Retrieved via AI Analytics 2026-05-29 from https://api.ai-analytics.org/clinical/NCT06102525. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*